EMERYVILLE, Calif.--(BUSINESS WIRE)-- <\/p>\n
KineMed, Inc. (www.kinemed.com) announced today that David Fineman, KineMeds CEO will present at the 2013 Biotech Showcase Conference on Monday, January 7th at 2:00 p.m. on the 4th floor of the Parc 55 Windham Hotel -- Union Square, San Francisco. <\/p>\n
Mr. Finemans presentation entitled Functionally Interpretable Translational Biomarkers for the Next Generation of Disease Management will present powerful examples of KineMeds new class of kinetic biomarker across the spectrum of medicines development and clinical care, from identifying the molecular causes of disease, to the pairing of drugs with diagnostics to treat patients more effectively. <\/p>\n
KineMeds unique signatures of disease state are derived from its proprietary Network Dynamics platform, which reveals causal relationships underlying the biology of disease mechanisms. These measurements of change are derived from ultra-sensitive, high-throughput mass spectroscopy of the entire proteome and metabolome. <\/p>\n
As our industry looks towards personalized medicine and the next generation of disease management, the indispensable role of biomarkers becomes increasingly clear, said Mr. Fineman. We are offering a truly universal method that is fully translational from preclinical R&D to clinical diagnostic measurements, all from a single drop of blood. At Biotech Showcase 2013, we will highlight successful examples of our unique approach across key indications including neurodegeneration, muscle wasting and fibrotic disease, showing how these techniques are becoming central to mainstream pharmaceutical development and disease management strategies. <\/p>\n
About Biotech Showcase <\/p>\n
Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industrys largest annual healthcare investor conferences. Now in its fifth year, Biotech Showcase is expected to attract upwards of 1,500 attendees. <\/p>\n
For more information about Biotech Showcase, please visit:http:\/\/www.ebdgroup.com\/bts\/index.php<\/a>. <\/p>\n About KineMed, Inc. <\/p>\n KineMed, Inc., is a leading diagnostic biomarker discovery and drug development company focused on causal pathway discovery and the pairing of medicines with diagnostics for integrated disease management. KineMed works with collaborators and clients to develop biomarkers that provide predictive, actionable information to dramatically improve, de-risk and accelerate drug discovery, development and disease management decisions. KineMeds technology reveals dynamic causal processes of disease rather than isolated molecular targets and provides precise measures of therapeutic effectiveness on these processes, offering yes\/no to key treatment questions: Is this drug right for the patient? and Is the drug working? <\/p>\n <\/p>\n Excerpt from: EMERYVILLE, Calif.--(BUSINESS WIRE)-- KineMed, Inc. (www.kinemed.com) announced today that David Fineman, KineMeds CEO will present at the 2013 Biotech Showcase Conference on Monday, January 7th at 2:00 p.m Continue reading
\nThe First Functionally Interpretable Systems Biology Platform for Personalized Medicine and Drug Development<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"